Navigation Links
Getting chemo first may help in rectal cancer
Date:5/15/2014

PROVIDENCE, R.I. [Brown University] First things first. If cancer patients are having trouble tolerating chemotherapy after chemoradiation and surgery, then try administering it beforehand. Reordering the regimen that way enabled all but six of 39 patients to undergo a full course of standard treatment for rectal cancer, according to research to be presented at the American Society for Clinical Oncology annual meeting in Chicago.

Studies have shown that only about 60 percent of rectal cancer patients comply with postoperative chemotherapy, said lead researcher Dr. Kimberly Perez, assistant professor of medicine in the Warren Alpert Medical School of Brown University and a cancer physician at Rhode Island Hospital. In the phase II trial, "Complete Neoadjuvant Therapy in Rectal Cancer" (CONTRE), more than 90 percent of the patients were able to complete a regimen of mFOLFOX6 when it was moved to the front of the line.

"The thought was, what can we do to make it more tolerable and get the benefit that we wanted," said Perez, who will speak at 4 p.m. CDT on Saturday, May 31, 2014 at ASCO. "It's encouraging because we were able to get the numbers up of patients who were able to get all the chemotherapy indicated."

All but one patient in the study underwent surgery and 85 percent underwent the middle step of chemoradiation after completing chemotherapy. The vast majority therefore received all three courses of standard treatment, albeit in a new order.

Almost all of the patients came into the study with rectal bleeding, but that symptom abated for all of them during treatment, Perez said.

Regarding the cancer itself, a majority of patients, 32 of whom entered the trial at stage III and seven of whom were less advanced at stage II, responded at least to some degree to the induction chemotherapy and chemoradiation treatments. By the time they got to surgery, 13 patients had no tumor left ("pathologic complete response"), 10 got all they way back to stage I, seven were at stage II, and eight remained at stage III.

The study occurred too recently, however, to provide a measure of overall survival, Perez acknowledged. The last patient finished surgery in January 2014.

The rate of side effects such as neutropenia, an adverse impact on the immune system, was not unusual.

The results of the CONTRE trial are now feeding into the development of a new national rectal cancer trial spearheaded by NRG Oncology, Perez said. That protocol will involve chemo first, then chemoradiation with biological anti-cancer agents, and finally surgery. Brown Univeristy Oncology Group and the Cancer Center of Rhode Island Hospital and associated satellites will be one of the study sites, Perez said.


'/>"/>

Contact: David Orenstein
david_orenstein@brown.edu
401-863-1862
Brown University
Source:Eurekalert  

Related medicine news :

1. Study: Women not getting enough exercise; at risk of developing metabolic syndrome
2. HPV vaccine completion rate among girls is poor, getting worse
3. American Kids Getting Fewer Prescription Drugs: Study
4. Getting your message across
5. Cholesterol Levels Getting Better for U.S. Kids: CDC
6. Kids need at least 7 minutes a day of vigorous physical activity, but most arent getting that
7. U.S. Kids Getting Enough Sleep After All: Survey
8. Fitquip: Getting Fit for Christmas on the Beach
9. New Blog Post from iHealthology.com Announces Why Staying Fit Means Getting on the Move
10. Quorn Foods Inc. Releases a Statement Following an Article on Getting the Most Out of a Vegetarian Healthy Food Diet
11. People with diabetes in Ontario getting fewer government-funded eye exams, new study finds
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Getting chemo first may help in rectal cancer
(Date:5/4/2016)... ... 2016 , ... Nordic Naturals announces another breakthrough innovation—Omega Curcumin, ... synergistic combination of omega-3 fatty acids and potent antioxidants contains 1000 mg concentrated ... and 200 mg of N-Acetylcysteine (NAC). , Each nutrient plays a distinct ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... pharmacy industry, today announced that it was chosen as the Pharmaceutical News Provider ... Awards . The awards acknowledge the hard work and dedication of community members ...
(Date:5/4/2016)... ... May 04, 2016 , ... AudioEducator is the country's top ... months, AudioEducator has lined up some informative training session for the medical coding ... compliance know-how and practical, easy-to-apply advice. , On Thursday, May 19, AudioEducator will ...
(Date:5/4/2016)... (PRWEB) , ... May 04, 2016 , ... ... Patient 2016, a powerful cellular therapy software application that helps blood and ... to patients. , Since Transtem’s initial launch, Mediware has continued to enhance core ...
(Date:5/4/2016)... (PRWEB) , ... May 04, 2016 , ... Fertility Centers ... at 535 Ocean Ave. Their new Maine Fertility Center provides convenient access to care ... Anne Rainville and her staff at Women’s Wellness Comprehensive Care in Portland,” said Fertility ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... ZIONA, Israel , May 4, ... TASE: BVXV) announced today that BiondVax,s CEO, Dr. Ron ... conference in New York City . ... at 10:30am at Pioneers 2016, a conference presented by ... York Palace Hotel. The BiondVax presentation that Dr. ...
(Date:5/4/2016)... , May 4, 2016 ... Jerusalem announced today that it had signed an ... Inc. , developer of novel protein degradation and immunomodulatory ... and commercialization of drug candidates representing first-in-class therapy for ... were not disclosed. The novel technology was ...
(Date:5/4/2016)... 2016 Valeritas Holdings, Inc. (OTCQB: ... public offering (APO). This was accomplished via a reverse ... and a private placement of approximately 5 million shares ... Under the terms of the reverse merger, ... Inc. will trade on the OTC Markets under the ...
Breaking Medicine Technology: